RDS welcomes MACSF as investor to help drive transformation of patient pathways

We are thrilled to announce a significant milestone for RDS, with the addition of MACSF to our portoflio of investors. This additionnal contribution of MACSF, combined with the existing €13 million seed funding, propels our total funding to €14 million ($15.3M) since our inception in 2020. RDS is now all focused on the last steps before commercialization. Stay tuned!

Read the full release here.